



Polymer, seen here microscopically, is used as a scaffold to grow new tissues. Matoka and colleagues review the basic technology in tissue engineering in urology and examine the current trends and future applicability of this technology. See page 403 for more.

Le polymère, vu ici au microscope, est utilisé comme échaffaud pour cultiver de nouveaux tissus. Le docteur Matoka et ses collègues passent en revue la technologie de base dans l'ingénierie tissulaire en urologie, et examinent les tendances actuelles ainsi que les applications futures de cette technologie. Veuillez vous référer à la page 403 pour obtenir plus de détails.

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.

Publications Mail Agreement no. 41614530. Return undeliverable Canadian copies to *CUAJ*, 1155 University Ave., Suite 1303, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41614530. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1303, Montréal QC H3B 3A7; journal@cua.org.

ISSN 1911-6470  
e-ISSN 1920-1214

### EDITORIAL

#### 359 Are we being seduced by a robot?

J.C. Nickel

### ÉDITORIAL

#### 362 Est-ce qu'on est séduit par un robot ?

J.C. Nickel

### CUA NEWS

#### 364 PEI 2010: Save the date!

J.B. Gajewski

### NOUVELLES DE L'AUC

#### 365 L'Î.-P.-É. 2010 : Gardez la date !

J.B. Gajewski

### ORIGINAL RESEARCH

#### 369 A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer

M. Hanninen, P. Venner, S. North

### COMMENTARY

#### 375 PSA-based treatment response criteria in castration-resistant prostate cancer: promises and limitations

U. Emmenegger, Y.J. Ko

### ORIGINAL RESEARCH

#### 377 Prediction of delayed graft function after renal transplantation

C. Jeldres, H. Cardinal, A. Duclos, S.F. Shariat, N. Suardi, U. Capitanio, M.J. Hébert, P.I. Karakiewicz

### ORIGINAL RESEARCH

#### 383 Perfusion CT evaluation in experimentally induced testicular torsion

G.Y. Ovali, O. Yilmaz, S. Tarhan, A. Genc, P. Demireli, O. Tunçyurek, C. Unden, C. Taneli, Y. Pabuscu

## COMMENTARY

- 387** Perfusion CT evaluation in experimentally induced testicular torsion: proceed with caution  
W.A. Farhat

## ORIGINAL RESEARCH

- 388** Knowledge about urology in the general population: alarming results  
L.O. Gagnon, A. Simard, L.M. Tu

## COMMENTARY

- 392** The public knows little about urology: How important is this?  
R. Casey

## ORIGINAL RESEARCH

- 393** Malignant lymphoma of the testis: a study of 12 cases  
A.G. Lantz, N. Power, B. Hutton, R. Gupta

## RESIDENT'S VIEW

- 399** Active learning: a resident's reflection on the impact of a student-centred curriculum  
J.J. Mickelson, W.E. Kaplan, A.E. MacNeily

## REVIEW

- 403** Tissue engineering in urology  
D.J. Matoka, E.Y. Cheng

## POINT/COUNTERPOINT

- 409** Radical cystectomy is the treatment of choice for invasive bladder cancer  
F.A. Yafi, W. Kassouf

- 412** In favour of bladder preservation using combined modality treatment  
H. Lukka

## CASE REPORTS

- 368** Listing of online case reports

## 428 IN MEMORIAM

## RESOURCES

- 375** Correction  
**416** Prescribing Index

### Visit [cuaj.ca](http://cuaj.ca) for more information:

- Instructions for Authors
- Instructions aux auteurs
- Urology Meetings of Interest
- Calendar of CME Events

## ADVERTISERS' INDEX / INDEX DES ANNONCEURS

**AMS Canada Inc.**  
InhibiZone 358  
**Astellas Pharma Canada**  
Vesicare 360, 418-9  
**AstraZeneca Canada Inc.**  
Zoladex LA Inside front cover, 427

**Clarion Medical Technologies Inc.**  
356  
**Merck Frosst Canada Ltd.**  
Proscar 366-7, 425-6  
**Pfizer Canada**  
Detrol 354, 416-7  
Sutent Back cover, 420-4